REMO HOLANDA DE MENDONCA FURTADO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54(2020) FURTADO, Remo H. M.; NICOLAU, Jose C.; MAGNANI, Giulia; IM, Kyungah; BHATT, Deepak L.; STOREY, Robert F.; STEG, P. Gabriel; SPINAR, Jindrich; BUDAJ, Andrzej; KONTNY, Frederic; CORBALAN, Ramon; KISS, Robert G.; ABOLA, Maria Teresa; JOHANSON, Per; JENSEN, Eva C.; BRAUNWALD, Eugene; SABATINE, Marc S.; BONACA, Marc P.Aims PEGASUS-TIMI 54 demonstrated that long-term dual antiplatelet therapy (DAPT) with aspirin and ticagrelor reduced the risk of major adverse cardiovascular events (MACE), with an acceptable increase in bleeding, in patients with prior myocardial infarction (MI). While much of the discussion around prolonged DAPT has been focused on stented patients, patients with prior MI without prior coronary stenting comprise a clinically important subgroup. Methods and results This was a pre-specified analysis from PEGASUS-TIMI 54, which randomized 21 162 patients with prior MI (1-3years) and additional high-risk features to ticagrelor 60 mg, 90 mg, or placebo twice daily in addition to aspirin. A total of 4199 patients had no history of coronary stenting at baseline. The primary efficacy outcome (MACE) was the composite of cardiovascular death, MI, or stroke. Patients without history of coronary stenting had higher baseline risk of MACE [13.2% vs. 8.0%, adjusted hazard ratio (HR) 1.41, 95% confidence interval (CI) 1.15-1.73, in the placebo arm]. The relative risk reduction in MACE with ticagrelor (pooled doses) was similar in patients without (HR 0.82, 95% CI 0.68-0.99) and with prior stenting (HR 0.85, 95% CI 0.75-0.96; P for interaction = 0.76). Conclusion Long-term ticagrelor reduces thrombotic events in patients with prior MI regardless of whether they had prior coronary stenting. These data highlight the benefits of DAPT in prevention of spontaneous atherothrombotic events and indicate that long-term ticagrelor may be considered in high-risk patients with prior MI even if they have not been treated with stenting.
conferenceObject Do women have worse response to P2Y12 antagonists than men after acute coronary syndrome?(2016) NICOLAU, J. C.; FERRARI, A. G.; DALCOQUIO, T.; FURTADO, R. H. M.; SCANAVINI, M. A.; NAKASHIMA, C. A. K.; ARANTES, F. B. B.; MENEZES, F. R.; LIMA, F. G.; BARACIOLI, L. M.; STRUNZ, C. M. C.; RAMIRES, J. A. F.; KALIL, R.conferenceObject Effect of exercise stress test on platelet function in patients with recent acute myocardial infarction(2019) DALCOQUIO, T.; SANTOS, M. A.; ALVES, L. S.; ARANTES, F. B. B.; FERREIRA-SANTOS, L.; RONDON, M. U. P. B.; ALVES, M. J. N. N.; FURTADO, R. H. M.; FERRARI, A. G.; GENESTRETI, P. R.; REALI, F. R.; RODRIGUEZ, M. R. S.; FRANCI, A.; NEGRAO, C. E.; NICOLAU, J. C.conferenceObject Platelet aggregability evaluation in patients with acute coronary syndromes scheduled for coronary artery bypass graft. The PLAT-CABG study(2019) NAKASHIMA, C. A. K.; DALLAN, L. A. O.; LISBOA, L. A. F.; HAJJAR, L. A.; SOEIRO, A. M.; SILVA, B. A.; COSTA, M. S. S.; DORNAS, C. J. C. B.; DALCOQUIO, T. F.; FURTADO, R. H. M.; BARACIOLI, L. M.; FUKUSHIMA, J. T.; GURBEL, P. A.; GIUGLIANO, R. P.; NICOLAU, J. C.conferenceObject Mean platelet volume and platelet reactivity in acute coronary syndromes: is there a correlation?(2016) NICOLAU, J. C.; DALCOQUIO, T. F.; FERRARI, A. G.; FURTADO, R. H. M.; NAKASHIMA, C. A. K.; SCANAVINI, M. A.; ARANTES, F. B. B.; MENEZES, F. R.; BARACIOLI, L. M.; RAMIRES, J. A. F.; STRUNZ, C. M. C.; KALIL, R.- Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial(2022) FONSECA, Henrique Andrade R.; FURTADO, Remo Holanda M.; ZIMERMAN, Andre; LEMOS, Pedro A.; FRANKEN, Marcelo; MONFARDINI, Frederico; PEDROSA, Rodrigo P.; PATRIOTA, Rodrigo de Lemos S.; PASSOS, Luiz Carlos S.; DALL'ORTO, Frederico Toledo C.; HOFFMANN FILHO, Conrado R.; NASCIMENTO, Bruno Ramos; BALDISSERA, Felipe A.; PEREIRA, Cesar Augusto C.; CARAMORI, Paulo Ricardo A.; ANDRADE, Pedro Beraldo de; ESTEVES, Carlos; SALIM, Elke Ferreira; SILVA, Jefferson Henrique da; PEDRO, Izabela Chave; SILVA, Mariana Castaldi R.; PEDRI, Ewerton Hernandes de; CARIOCA, Ana Carla R. D.; PIANO, Luciana Pereira A. de; ALBUQUERQUE, Camila Santos N.; MOIA, Diogo D. F.; MOMESSO, Roberta Grazzielli R. A. P.; MACHADO, Felipe P.; DAMIANI, Lucas P.; SOARES, Ronaldo Vicente P.; SCHETTINO, Guilherme P.; V, Luiz Rizzo; NICOLAU, Jose Carlos; BERWANGER, OtavioAims To evaluate whether a strategy of double-dose influenza vaccination during hospitalization for an acute coronary syndrome (ACS) compared with standard-dose outpatient vaccination (as recommended by current guidelines) would further reduce the risk of major cardiopulmonary events. Methods and results Vaccination against Influenza to Prevent cardiovascular events after Acute Coronary Syndromes (VIP-ACS) was a pragmatic, randomized, multicentre, active-comparator, open-label trial with blinded outcome adjudication comparing two strategies of influenza vaccination following an ACS: double-dose quadrivalent inactivated vaccine before hospital discharge vs. standard-dose quadrivalent inactivated vaccine administered in the outpatient setting 30 days after randomization. The primary outcome was a hierarchical composite of all-cause death, myocardial infarction, stroke, unstable angina, hospitalization for heart failure, urgent coronary revascularization, and hospitalization for respiratory causes, analysed by the win ratio method. Patients were followed for 12 months. During two influenza seasons, 1801 participants were included at 25 centres in Brazil. The primary outcome was not different between groups, with 12.7% wins in-hospital double-dose vaccine group and 12.3% wins in the standard-dose vaccine group {win ratio: 1.02 [95% confidence interval (CI): 0.79-1.32], P = 0.84}. Results were consistent for the key secondary outcome, a hierarchical composite of cardiovascular death, myocardial infarction and stroke [win ratio: 0.94 (95% CI: 0.66-1.33), P = 0.72]. Time-to-first event analysis for the primary outcome showed results similar to those of the main analysis [hazard ratio 0.97 (95% CI: 0.75-1.24), P = 0.79]. Adverse events were infrequent and did not differ between groups. Conclusion Among patients hospitalized with an ACS, double-dose influenza vaccination before discharge did not reduce cardiopulmonary outcomes compared with standard-dose vaccination in the outpatient setting.
conferenceObject Predictors of returning to work in the long-run after an acute coronary syndrome episode(2018) NICOLAU, J. C.; LARA, L.; DALCOQUIO, T.; BARACIOLI, L. M.; FURTADO, R. H. M.; FRANCI, A.; COSTA, M. S. S.; FERRARI, A. G.; SCANAVINI FILHO, M. A.; GODOY, L. C.; RAMIRES, J. A. F.; KALIL-FILHO, R.; SILVA, J. C.conferenceObject Statin therapy improves glycemic control in diabetic patients admitted with acute coronary syndromes(2017) FURTADO, R. H. M.; DALCOQUIO, T. F.; BARACIOLI, L. M.; LIMA, F. G.; FRANCI, A.; MENEZES, F. R.; GENESTRETI, P. R. R.; FERRARI, A. G.; LIMA, V. M.; KALIL FILHO, R.; NICO-LAU, J. C.conferenceObject Impact of ranitidine on platelet aggregation in patients taking clopidogrel(2013) FURTADO, R. H. M.; FRANCI, A.; BARBOSA, C. J. D. G.; GIANNETTI, N. S.; D'AMICO, E. A.; STRUNZ, C. M. C.; BARACIOLI, L. M.; FRANKEN, M.; LIMA, F. G.; NICOLAU, J. C.conferenceObject Early oral betablocker utilization reduces in-hospital mortality in patients submitted to primary percutaneous coronary intervention: a real-world analysis(2017) FURTADO, R. H. M.; DALCOQUIO, T. F.; NAKASHIMA, C. A. K.; SCANAVINI FILHO, M. A.; PEREIRA, C. A. C.; LARA, L. M.; GANEM, F.; GIRALDEZ, R. R. C. V.; FRANKEN, M.; KALIL FILHO, R.; NICOLAU, J. C.